Literature DB >> 32200464

HOXB13 expression is correlated with hepatic inflammatory activity of patients with hepatic fibrosis.

Lingyun Zuo1,2, Tingting Tan3, Cheng Wei2, Huali Wang2, Luxuan Tan2, Yingying Hao4, Jingjing Qian2, Yuxin Chen5, Chao Wu6.   

Abstract

Liver fibrosis is a common pathological process of chronic hepatic injury, preceded by the chronic inflammation. The homeobox B13 (HOXB13) gene, a member of HOX family, plays diverse biological roles in embryonic development, carcinogenesis, and many inflammatory diseases. However, the expression of HOXB13 in chronic liver diseases including hepatic fibrosis remains to be defined. In present study, 55 patients with hepatic fibrosis, 15 patients of hepatocellular carcinoma, and 17 healthy controls were enrolled in this study. Pathological specimens were collected through liver biopsy or surgical resection. The degree of hepatic inflammation (G0-G4) and fibrosis (S0-S4) of hepatic fibrosis was scored based on the modified histology activity index. Intrahepatic HOXB13 expression was analyzed using immunohistochemistry analysis. Compared with healthy subjects, both patients with hepatic fibrosis and patients with hepatocellular carcinoma exhibited significant accumulations of HOXB13+ cells in the liver (p < 0.05). Additionally, the number of HOXB13+ cell was significantly elevated along with the increment of hepatic inflammatory activities, but not fibrosis stages, among these liver fibrosis samples (p < 0.01). Furthermore, the quantity of HOXB13+ cells were also positively correlated with hepatic enzymes, alanine transaminase (r = 0.299, p = 0.041) and aspartate aminotransferase (r = 0.317, p = 0.013) in our cohort of hepatic fibrosis. In conclusion, our study identified a strong hepatic expression of HOXB13 among patients with hepatic fibrosis, which strongly associated with the degree of hepatic inflammatory activity for patients with hepatic fibrosis, suggesting an important role of HOXB13 during the pathogenesis of liver fibrogenesis.

Entities:  

Keywords:  HOXB13; Hepatic fibrosis; Hepatic inflammatory activity

Mesh:

Substances:

Year:  2020        PMID: 32200464     DOI: 10.1007/s10735-020-09868-7

Source DB:  PubMed          Journal:  J Mol Histol        ISSN: 1567-2379            Impact factor:   2.611


  24 in total

Review 1.  Pathogenesis of liver fibrosis.

Authors:  Virginia Hernandez-Gea; Scott L Friedman
Journal:  Annu Rev Pathol       Date:  2011       Impact factor: 23.472

2.  Curcumin reduces Ly6Chi monocyte infiltration to protect against liver fibrosis by inhibiting Kupffer cells activation to reduce chemokines secretion.

Authors:  Xiang-An Zhao; Guangmei Chen; Yong Liu; Yuxin Chen; Hongyan Wu; Yali Xiong; Guiyang Wang; Bei Jia; Yang Li; Juan Xia; Jian Wang; Xiaomin Yan; Zhaoping Zhang; Rui Huang; Chao Wu
Journal:  Biomed Pharmacother       Date:  2018-07-11       Impact factor: 6.529

3.  Epigenetic silencing of novel tumor suppressors in malignant melanoma.

Authors:  Viswanathan Muthusamy; Sekhar Duraisamy; C Matthew Bradbury; Cara Hobbs; David P Curley; Betsy Nelson; Marcus Bosenberg
Journal:  Cancer Res       Date:  2006-12-01       Impact factor: 12.701

4.  High-level expression of HOXB13 is closely associated with tumor angiogenesis and poor prognosis of hepatocellular carcinoma.

Authors:  Jian-Yu Zhu; Qi-Kai Sun; Wei Wang; Wei-Dong Jia
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

5.  Suppression of invasive characteristics by antisense introduction of overexpressed HOX genes in ovarian cancer cells.

Authors:  Tsuyoshi Yamashita; Seishiro Tazawa; Zhao Yawei; Hideto Katayama; Yasuhito Kato; Kunihiko Nishiwaki; Yuko Yokohama; Mutsuo Ishikawa
Journal:  Int J Oncol       Date:  2006-04       Impact factor: 5.650

6.  Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors: 
Journal:  Lancet       Date:  2014-12-18       Impact factor: 79.321

7.  Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes.

Authors:  Z Kote-Jarai; C Mikropoulos; D A Leongamornlert; T Dadaev; M Tymrakiewicz; E J Saunders; M Jones; S Jugurnauth-Little; K Govindasami; M Guy; F C Hamdy; J L Donovan; D E Neal; J A Lane; D Dearnaley; R A Wilkinson; E J Sawyer; A Morgan; A C Antoniou; R A Eeles
Journal:  Ann Oncol       Date:  2015-01-16       Impact factor: 32.976

8.  Evaluation of HOXB13 as a molecular marker of recurrent prostate cancer.

Authors:  Tae-O Jeong; Kyung-Jin Oh; Nguyen Thi Xuan Nguyen; Young-Rang Kim; Min Soo Kim; Sang Don Lee; Soo Bang Ryu; Chaeyong Jung
Journal:  Mol Med Rep       Date:  2012-01-30       Impact factor: 2.952

9.  HOXB13 is downregulated in colorectal cancer to confer TCF4-mediated transactivation.

Authors:  C Jung; R-S Kim; H Zhang; S-J Lee; H Sheng; P J Loehrer; T A Gardner; M-H Jeng; C Kao
Journal:  Br J Cancer       Date:  2005-06-20       Impact factor: 7.640

10.  Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer.

Authors:  Stella Tommasi; Deborah L Karm; Xiwei Wu; Yun Yen; Gerd P Pfeifer
Journal:  Breast Cancer Res       Date:  2009-02-27       Impact factor: 6.466

View more
  2 in total

1.  A microRNA‑17‑5p/homeobox B13 axis participates in the phenotypic modulation of vascular smooth muscle cells.

Authors:  Tianchi Yu; Tao Wang; Shifang Kuang; Guoping Zhao; Kun Zhou; Hui Zhang
Journal:  Mol Med Rep       Date:  2021-08-20       Impact factor: 2.952

2.  Deriving time-concordant event cascades from gene expression data: A case study for Drug-Induced Liver Injury (DILI).

Authors:  Anika Liu; Namshik Han; Jordi Munoz-Muriedas; Andreas Bender
Journal:  PLoS Comput Biol       Date:  2022-06-10       Impact factor: 4.779

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.